ATE218892T1 - Affinitätsmarkierer für menschliches serum albumin - Google Patents

Affinitätsmarkierer für menschliches serum albumin

Info

Publication number
ATE218892T1
ATE218892T1 AT98959387T AT98959387T ATE218892T1 AT E218892 T1 ATE218892 T1 AT E218892T1 AT 98959387 T AT98959387 T AT 98959387T AT 98959387 T AT98959387 T AT 98959387T AT E218892 T1 ATE218892 T1 AT E218892T1
Authority
AT
Austria
Prior art keywords
serum albumin
human serum
affinity marker
molecule
affinity
Prior art date
Application number
AT98959387T
Other languages
English (en)
Inventor
Alexander Krantz
Wolin Huang
Arthur M Hanel
Darren L Holmes
Dominique P Bridon
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE218892T1 publication Critical patent/ATE218892T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98959387T 1997-11-07 1998-11-06 Affinitätsmarkierer für menschliches serum albumin ATE218892T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07
US7792798P 1998-03-13 1998-03-13
PCT/US1998/023705 WO1999024075A2 (en) 1997-11-07 1998-11-06 Affinity markers for human serum albumin

Publications (1)

Publication Number Publication Date
ATE218892T1 true ATE218892T1 (de) 2002-06-15

Family

ID=26744806

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98959387T ATE218892T1 (de) 1997-11-07 1998-11-06 Affinitätsmarkierer für menschliches serum albumin
AT01126379T ATE406577T1 (de) 1997-11-07 1998-11-06 Methoden zum screening von affinitätsmarker- bibliotheken

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01126379T ATE406577T1 (de) 1997-11-07 1998-11-06 Methoden zum screening von affinitätsmarker- bibliotheken

Country Status (8)

Country Link
US (1) US7166695B2 (de)
EP (2) EP1056474B1 (de)
AT (2) ATE218892T1 (de)
AU (1) AU1519699A (de)
CA (2) CA2628053A1 (de)
DE (2) DE69839946D1 (de)
ES (1) ES2178854T3 (de)
WO (1) WO1999024075A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
JP4217004B2 (ja) * 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド 血液成分への結合体化を介するペプチダーゼ活性からの内因性治療用ペプチドの保護
CA2363712C (en) 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
ES2334106T3 (es) * 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
AU764103B2 (en) * 1999-05-17 2003-08-07 Conjuchem Biotechnologies Inc. Long lasting anti-angiogenic peptides
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
EA006484B1 (ru) 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
US7112567B2 (en) 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
ATE412667T1 (de) 2001-05-31 2008-11-15 Conjuchem Biotechnologies Inc Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
ATE466953T1 (de) 2003-01-17 2010-05-15 Advanced Proteome Therapeutics Verfahren zur identifizierung aktivierter polymer-komplexe zur sekundären stellen-spezifischen modifikation von protein ziel-gruppen.
PL1745078T3 (pl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Sposób oczyszczania koniugatów albumin
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
JP2009520469A (ja) * 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
EP3413921A4 (de) * 2016-02-09 2019-08-14 Alexander Krantz Ortsselektive funktionalisierung von proteinen mittels spurloser affinitätsmarkierungen
CN110637036A (zh) * 2017-04-28 2019-12-31 味之素株式会社 具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862928A (en) * 1969-07-09 1975-01-28 Akzona Inc Psychopharmacological hexa-peptides containing a d-phenylalanyl residue
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4933288A (en) * 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
DE3731297C1 (de) 1987-09-17 1989-05-18 Rexroth Mannesmann Gmbh Schaltventilanordnung
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
KR100195632B1 (ko) * 1988-07-23 1999-06-15 스티븐 조지 가랜드 펩티드 및 dna 배열
WO1990003799A1 (en) * 1988-10-12 1990-04-19 Centocor, Inc. Radiotherapeutic immunoconjugates labeled with iodine-125
US5250662A (en) * 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5182366A (en) 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JP3523252B2 (ja) 1990-11-21 2004-04-26 ホウテン ファーマシューティカルズ インコーポレイテッド 等モル多種オリゴマー混合物、特にオリゴペプチド混合物の合成
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
JPH0692968A (ja) * 1992-09-16 1994-04-05 Nakarai Tesuku Kk ビオチン導入試薬
KR0168709B1 (ko) 1992-09-24 1999-01-15 윌리엄 지. 그린 N-치환 올리고머의 합성
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5571681A (en) * 1994-03-10 1996-11-05 The Scripps Research Institute Chemical event selection by suicide substrate conjugates
JP2000502897A (ja) 1995-12-18 2000-03-14 プレーシス ファーマスーティカルズ インコーポレイテッド 標的に結合する化合物を同定する方法
AU713616B2 (en) * 1996-01-12 1999-12-09 Conjuchem, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
AU4351897A (en) 1996-09-16 1998-04-02 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
US6203820B1 (en) * 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification

Also Published As

Publication number Publication date
EP1056474A2 (de) 2000-12-06
ES2178854T3 (es) 2003-01-01
EP1056474B1 (de) 2002-06-12
US20050037974A1 (en) 2005-02-17
CA2305597A1 (en) 1999-05-20
DE69806066T2 (de) 2003-02-06
DE69839946D1 (de) 2008-10-09
CA2628053A1 (en) 1999-05-20
WO1999024075A3 (en) 1999-09-02
AU1519699A (en) 1999-05-31
US7166695B2 (en) 2007-01-23
DE69806066D1 (de) 2002-07-18
CA2305597C (en) 2008-07-29
ATE406577T1 (de) 2008-09-15
EP2033661A1 (de) 2009-03-11
WO1999024075A2 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
ATE218892T1 (de) Affinitätsmarkierer für menschliches serum albumin
DE69731476D1 (de) Kupplungen für medizinische kanülen
DE69525293D1 (de) Inhalationsgerät für medizinische Zwecke
ID22977A (id) Konjugasi polietilen glikol-interferon alfa untuk terapi suatu infeksi
DE50014571D1 (de) Träger-pharmaka-konjugate
FR06C0024I2 (fr) Anticorps humanises diriges contre la molecule d'adhesion leucocytaire vla-4
DE69608498D1 (de) Ventilanschluss für medizinische Injektionsstelle
DE69932918D1 (de) Kupplung für medizinische Kanülen
DE69834596D1 (de) Etectrochirurghische, blutstillende klammervorrichtung
DE69800460D1 (de) Katheteranordnung zum intrakardialen Nähen
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
FI970957A7 (fi) Automaattinen molekyyli-biologinen diagnostiikkajärjestelmä
EA200000427A1 (ru) Терапевтические применения хинолиновых производных
DE69737600D1 (de) Membranen für medizinische anwendungen
DE59600733D1 (de) Chirurgischer Gefässclip
DK0627940T3 (da) Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
DE69700384D1 (de) Telemetriesystem, insbesondere für medizinische Zwecke
FI973002L (fi) Terapeuttinen yhdiste - rasvahappokonjugaatit
EP0749320A4 (de) Fibrin spezifischer antikörper zur verwendung als antithrombose agenz
TR199600753A1 (tr) Ikame edilmis benzoilguanidin'leri, bunlarin imal edilmesine mahsus usul, bunlarin ilac ya da diyagnoz maddesi olarak kullanilmalari ve ayrica bunlari ihtiva eden ilaclar.
NO914839D0 (no) Merkete, modifiserte oligonukleotider
DE69513747D1 (de) Ventilanschluss für medizinische Injektionsstelle
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor
DE69722221D1 (de) Montagesystem für krankenhäuser
FR2718448B3 (fr) Dérivés d'acides aminoboroniques, leur préparation et leur utilisation comme intermédiaires de synthèse.